SUBSCRIBE
SUBSCRIBE
News   Drug Development

Valeant Pharmaceuticals International May Fall if New Drug Disappoints-Barron’s

November 23, 2009 | 
1 min read
Bookmark and Share

Reuters -- Investors could shave off a third of the valuation of Valeant Pharmaceuticals International (VRX.N) if its prospective epilepsy drug retigabine fails to live up to expectations, according to a Barron's report.
Clinical research Phase 2
MORE ON THIS TOPIC
Illustration of scales of justice tipping to one side
Lung cancer
Despite 3 patient deaths, Cullinan-Taiho plan FDA filing for lung cancer pill on survival benefit
September 15, 2026
 · 
3 min read
 · 
Tristan Manalac
United Kingdom and China flag together realtions textile cloth fabric texture
Deals
GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M
September 15, 2026
 · 
2 min read
 · 
Gabrielle Masson
Model of the lungs with the diseased part. Cancer or Ground glass opacity GGO.
Lung cancer
Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
September 14, 2026
 · 
4 min read
 · 
Gabrielle Masson
This 3D rendering encapsulates the concept of a winning strategy in business, emphasizing productivity, innovation, and the importance of female leadership. The imagery represents the synergy of teamwork, where diverse ideas and collaborative efforts drive success and growth. It highlights the critical role of women in leadership positions, showcasing their contributions to strategic planning and innovation. This visual serves as an inspiring representation of how inclusive leadership and innovative thinking can propel a business toward achieving its goals and maintaining a competitive edge in the market.
Psychedelics
Definium moves toward FDA submission for LSD drug in anxiety after ‘another clear win’
September 14, 2026
 · 
3 min read
 · 
Heather McKenzie